首页 > 最新文献

Current drug delivery最新文献

英文 中文
The Fate of 1,8-cineole as a Chemical Penetrant: A Review. 作为化学渗透剂的 1,8-蒎烯的命运:综述。
IF 2.4 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-01-01 DOI: 10.2174/1567201820666230509101602
Ligema Dao, Yu Dong, Lin Song, Chula Sa

The stratum corneum continues to pose the biggest obstacle to transdermal drug delivery. Chemical penetrant, the first generation of transdermal drug delivery system, offers a lot of potential. In order to fully examine the permeation mechanism of 1,8-cineole, a natural monoterpene, this review summarizes the effects of permeation-enhancing medications on drugs that are lipophilic and hydrophilic as well as the toxicity of this substance on the skin and other tissues. For lower lipophilic drugs, 1,8-cineole appears to have a stronger osmotic-enhancing impact. An efficient and secure tactic would be to combine enhancers and dose forms. 1,8-cineole is anticipated to be further developed in the transdermal drug delivery system and even become a candidate drug for brain transport due to its permeability and low toxicity.

角质层仍然是透皮给药的最大障碍。化学渗透剂作为第一代透皮给药系统,具有很大的潜力。为了全面研究天然单萜类化合物 1,8-蒎烯的渗透机制,本综述总结了渗透促进剂对亲脂性和亲水性药物的影响,以及这种物质对皮肤和其他组织的毒性。对于亲脂性较低的药物,1,8-松油醇似乎具有更强的渗透促进作用。一种有效而安全的方法是将增强剂和剂型结合起来。1,8-ineole 因其渗透性和低毒性,有望在透皮给药系统中得到进一步开发,甚至成为脑部转运的候选药物。
{"title":"The Fate of 1,8-cineole as a Chemical Penetrant: A Review.","authors":"Ligema Dao, Yu Dong, Lin Song, Chula Sa","doi":"10.2174/1567201820666230509101602","DOIUrl":"10.2174/1567201820666230509101602","url":null,"abstract":"<p><p>The stratum corneum continues to pose the biggest obstacle to transdermal drug delivery. Chemical penetrant, the first generation of transdermal drug delivery system, offers a lot of potential. In order to fully examine the permeation mechanism of 1,8-cineole, a natural monoterpene, this review summarizes the effects of permeation-enhancing medications on drugs that are lipophilic and hydrophilic as well as the toxicity of this substance on the skin and other tissues. For lower lipophilic drugs, 1,8-cineole appears to have a stronger osmotic-enhancing impact. An efficient and secure tactic would be to combine enhancers and dose forms. 1,8-cineole is anticipated to be further developed in the transdermal drug delivery system and even become a candidate drug for brain transport due to its permeability and low toxicity.</p>","PeriodicalId":10842,"journal":{"name":"Current drug delivery","volume":" ","pages":"697-708"},"PeriodicalIF":2.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9796488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nanotechnology-based Drug Delivery for Alzheimer's and Parkinson's Diseases. 基于纳米技术的阿尔茨海默氏症和帕金森氏症药物输送。
IF 2.4 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-01-01 DOI: 10.2174/1567201820666230707113405
Phuong-Trang Nguyen-Thi, Thanh-Tam Ho, Thuy Trang Nguyen, Giau Van Vo

The delivery of drugs to the brain is quite challenging in the treatment of the central nervous system (CNS) diseases due to the blood-brain barrier and the blood-cerebrospinal fluid barrier. However, significant developments in nanomaterials employed by nanoparticle drug-delivery systems have substantial potential to cross or bypass these barriers leading to enhanced therapeutic efficacies. Advances in nanoplatform, nanosystems based on lipids, polymers and inorganic materials have been extensively studied and applied in treating Alzheimer's and Parkinson's diseases. In this review, various types of brain drug delivery nanocarriers are classified, summarized, and their potential as drug delivery systems in Alzheimer's and Parkinson's diseases is discussed. Finally, challenges facing the clinical translation of nanoparticles from bench to bedside are highlighted.

由于血脑屏障和血-脑脊液屏障的存在,在治疗中枢神经系统(CNS)疾病的过程中,向大脑输送药物具有相当大的挑战性。然而,纳米颗粒给药系统所采用的纳米材料的重大发展具有跨越或绕过这些屏障、提高疗效的巨大潜力。基于脂质、聚合物和无机材料的纳米平台和纳米系统的进步已被广泛研究并应用于治疗阿尔茨海默氏症和帕金森氏症。在这篇综述中,对各种类型的脑给药纳米载体进行了分类和总结,并讨论了它们作为阿尔茨海默氏症和帕金森氏症给药系统的潜力。最后,重点介绍了纳米颗粒从实验室到临床应用所面临的挑战。
{"title":"Nanotechnology-based Drug Delivery for Alzheimer's and Parkinson's Diseases.","authors":"Phuong-Trang Nguyen-Thi, Thanh-Tam Ho, Thuy Trang Nguyen, Giau Van Vo","doi":"10.2174/1567201820666230707113405","DOIUrl":"10.2174/1567201820666230707113405","url":null,"abstract":"<p><p>The delivery of drugs to the brain is quite challenging in the treatment of the central nervous system (CNS) diseases due to the blood-brain barrier and the blood-cerebrospinal fluid barrier. However, significant developments in nanomaterials employed by nanoparticle drug-delivery systems have substantial potential to cross or bypass these barriers leading to enhanced therapeutic efficacies. Advances in nanoplatform, nanosystems based on lipids, polymers and inorganic materials have been extensively studied and applied in treating Alzheimer's and Parkinson's diseases. In this review, various types of brain drug delivery nanocarriers are classified, summarized, and their potential as drug delivery systems in Alzheimer's and Parkinson's diseases is discussed. Finally, challenges facing the clinical translation of nanoparticles from bench to bedside are highlighted.</p>","PeriodicalId":10842,"journal":{"name":"Current drug delivery","volume":" ","pages":"917-931"},"PeriodicalIF":2.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10123082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nano-platform Strategies of Herbal Components for the Management of Rheumatoid Arthritis: A Review on the Battle for Next-Generation Formulations. 治疗类风湿性关节炎的草药成分纳米平台战略:新一代制剂之争综述》。
IF 2.4 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-01-01 DOI: 10.2174/1567201821666230825102748
Jyoti Prabha, Mohit Kumar, Devesh Kumar, Shruti Chopra, Amit Bhatia

Introduction: Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease that initially affects small joints and then spreads to the bigger joints. It also affects other organs of the body such as lungs, eyes, kidneys, heart, and skin. In RA, there is destruction of cartilage and joints, and ligaments and tendons become brittle. Damage to the joints leads to abnormalities and bone degradation, which may be quite painful for the patient.

Method: The nano-carriers such as liposomes, phytosomes, nanoparticles, microcapsules, and niosomes are developed to deliver the encapsulated phytoconstituents to targeted sites for the better management of RA.

Results: The phytoconstituents loaded nano-carriers have been used in order to increase bioavailability, stability and reduce the dose of an active compound. In one study, the curcumin-loaded phytosomes increase the bioavailability of curcumin and also provides relief from RA symptoms. The drug-loaded nano-carriers are the better option for the management of RA.

Conclusion: In conclusion, there are many anti-arthritic herbal and synthetic medicine available in the market that are currently used in the treatment of RA. However, chronic use of these medications may result in a variety of side effects. Because therapy for RA is frequently necessary for the rest of ones life. The use of natural products may be a better option for RA management. These phytoconstituents, however, have several disadvantages, including limited bioavailability, low stability, and the need for a greater dosage. These problems can be rectified by using nano-technology.

导言类风湿性关节炎(RA)是一种慢性炎症性自身免疫疾病,最初会影响小关节,然后扩散到大关节。它还会影响身体的其他器官,如肺、眼睛、肾脏、心脏和皮肤。患上 RA 后,软骨和关节会遭到破坏,韧带和肌腱也会变脆。关节受损会导致畸形和骨质退化,这可能会给患者带来相当大的痛苦:方法:开发纳米载体,如脂质体、植物载体、纳米颗粒、微胶囊和niosomes,将封装的植物成分输送到目标部位,以更好地治疗RA:结果:载入纳米载体的植物成分已被用于提高生物利用度、稳定性和减少活性化合物的剂量。在一项研究中,载入姜黄素的植物载体提高了姜黄素的生物利用率,还能缓解 RA 症状。载药纳米载体是治疗风湿性关节炎的更好选择:总之,目前市场上有许多抗关节炎的草药和合成药物可用于治疗 RA。然而,长期使用这些药物可能会导致各种副作用。因为 RA 的治疗往往需要终生进行。使用天然产品可能是治疗 RA 的更好选择。然而,这些植物成分有几个缺点,包括生物利用度有限、稳定性低和需要更大的剂量。利用纳米技术可以解决这些问题。
{"title":"Nano-platform Strategies of Herbal Components for the Management of Rheumatoid Arthritis: A Review on the Battle for Next-Generation Formulations.","authors":"Jyoti Prabha, Mohit Kumar, Devesh Kumar, Shruti Chopra, Amit Bhatia","doi":"10.2174/1567201821666230825102748","DOIUrl":"10.2174/1567201821666230825102748","url":null,"abstract":"<p><strong>Introduction: </strong>Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease that initially affects small joints and then spreads to the bigger joints. It also affects other organs of the body such as lungs, eyes, kidneys, heart, and skin. In RA, there is destruction of cartilage and joints, and ligaments and tendons become brittle. Damage to the joints leads to abnormalities and bone degradation, which may be quite painful for the patient.</p><p><strong>Method: </strong>The nano-carriers such as liposomes, phytosomes, nanoparticles, microcapsules, and niosomes are developed to deliver the encapsulated phytoconstituents to targeted sites for the better management of RA.</p><p><strong>Results: </strong>The phytoconstituents loaded nano-carriers have been used in order to increase bioavailability, stability and reduce the dose of an active compound. In one study, the curcumin-loaded phytosomes increase the bioavailability of curcumin and also provides relief from RA symptoms. The drug-loaded nano-carriers are the better option for the management of RA.</p><p><strong>Conclusion: </strong>In conclusion, there are many anti-arthritic herbal and synthetic medicine available in the market that are currently used in the treatment of RA. However, chronic use of these medications may result in a variety of side effects. Because therapy for RA is frequently necessary for the rest of ones life. The use of natural products may be a better option for RA management. These phytoconstituents, however, have several disadvantages, including limited bioavailability, low stability, and the need for a greater dosage. These problems can be rectified by using nano-technology.</p>","PeriodicalId":10842,"journal":{"name":"Current drug delivery","volume":" ","pages":"1082-1105"},"PeriodicalIF":2.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10069389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Magnetosomes as Potential Nanocarriers for Cancer Treatment. 磁小体作为治疗癌症的潜在纳米载体
IF 2.4 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-01-01 DOI: 10.2174/1567201820666230619155528
Rawan Alsharedeh, Nid'a Alshraiedeh, Alaa A Aljabali, Murtaza M Tambuwala

Magnetotactic bacteria (MTBs) and their organelles, magnetosomes, are intriguing options that might fulfill the criteria of using bacterial magnetosomes (BMs). The ferromagnetic crystals contained in BMs can condition the magnetotaxis of MTBs, which is common in water storage facilities. This review provides an overview of the feasibility of using MTBs and BMs as nanocarriers in cancer treatment. More evidence suggests that MTBs and BMs can be used as natural nanocarriers for conventional anticancer medicines, antibodies, vaccine DNA, and siRNA. In addition to improving the stability of chemotherapeutics, their usage as transporters opens the possibilities for the targeted delivery of single ligands or combinations of ligands to malignant tumors. Magnetosome magnetite crystals are different from chemically made magnetite nanoparticles (NPs) because they are strong single-magnetic domains that stay magnetized even at room temperature. They also have a narrow size range and a uniform crystal morphology. These chemical and physical properties are essential for their usage in biotechnology and nanomedicine. Bioremediation, cell separation, DNA or antigen regeneration, therapeutic agents, enzyme immobilization, magnetic hyperthermia, and contrast enhancement of magnetic resonance are just a few examples of the many uses for magnetite-producing MTB, magnetite magnetosomes, and magnetosome magnetite crystals. From 2004 to 2022, data mining of the Scopus and Web of Science databases showed that most research using magnetite from MTB was carried out for biological reasons, such as in magnetic hyperthermia and drug delivery.

趋磁细菌(MTBs)及其细胞器--磁小体,是可能符合细菌磁小体(BMs)使用标准的令人感兴趣的选择。磁小体中含有的铁磁晶体可以调节 MTB 的磁向性,这在储水设施中很常见。本综述概述了在癌症治疗中使用 MTB 和 BM 作为纳米载体的可行性。更多证据表明,MTB 和 BMs 可用作常规抗癌药物、抗体、疫苗 DNA 和 siRNA 的天然纳米载体。除了提高化疗药物的稳定性外,将它们用作转运体还为向恶性肿瘤靶向输送单一配体或配体组合提供了可能性。磁小体磁铁矿晶体不同于化学制造的磁铁矿纳米颗粒(NPs),因为它们是即使在室温下也能保持磁化的强单磁畴。它们还具有较窄的尺寸范围和均匀的晶体形态。这些化学和物理特性对它们在生物技术和纳米医学中的应用至关重要。生物修复、细胞分离、DNA 或抗原再生、治疗剂、酶固定化、磁性热疗和磁共振对比度增强只是产生磁铁矿的 MTB、磁铁矿磁小体和磁小体磁铁矿晶体众多用途中的几个例子。从 2004 年到 2022 年,对 Scopus 和 Web of Science 数据库进行的数据挖掘显示,利用 MTB 产生的磁铁矿进行的大多数研究都是出于生物学原因,如磁性热疗和药物输送。
{"title":"Magnetosomes as Potential Nanocarriers for Cancer Treatment.","authors":"Rawan Alsharedeh, Nid'a Alshraiedeh, Alaa A Aljabali, Murtaza M Tambuwala","doi":"10.2174/1567201820666230619155528","DOIUrl":"10.2174/1567201820666230619155528","url":null,"abstract":"<p><p>Magnetotactic bacteria (MTBs) and their organelles, magnetosomes, are intriguing options that might fulfill the criteria of using bacterial magnetosomes (BMs). The ferromagnetic crystals contained in BMs can condition the magnetotaxis of MTBs, which is common in water storage facilities. This review provides an overview of the feasibility of using MTBs and BMs as nanocarriers in cancer treatment. More evidence suggests that MTBs and BMs can be used as natural nanocarriers for conventional anticancer medicines, antibodies, vaccine DNA, and siRNA. In addition to improving the stability of chemotherapeutics, their usage as transporters opens the possibilities for the targeted delivery of single ligands or combinations of ligands to malignant tumors. Magnetosome magnetite crystals are different from chemically made magnetite nanoparticles (NPs) because they are strong single-magnetic domains that stay magnetized even at room temperature. They also have a narrow size range and a uniform crystal morphology. These chemical and physical properties are essential for their usage in biotechnology and nanomedicine. Bioremediation, cell separation, DNA or antigen regeneration, therapeutic agents, enzyme immobilization, magnetic hyperthermia, and contrast enhancement of magnetic resonance are just a few examples of the many uses for magnetite-producing MTB, magnetite magnetosomes, and magnetosome magnetite crystals. From 2004 to 2022, data mining of the Scopus and Web of Science databases showed that most research using magnetite from MTB was carried out for biological reasons, such as in magnetic hyperthermia and drug delivery.</p>","PeriodicalId":10842,"journal":{"name":"Current drug delivery","volume":" ","pages":"1073-1081"},"PeriodicalIF":2.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9667269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Liposomal Doxorubicin In vitro and In vivo Assays in Non-small Cell Lung Cancer: A Systematic Review 多柔比星脂质体在非小细胞肺癌中的体外和体内试验:系统综述
IF 2.4 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2023-12-15 DOI: 10.2174/0115672018272162231116093143
Pablo Redruello-Guerrero, Paula Cordoba, Antonio Láinez-Ramos-Bossini, Mario Rivera, Cristina Mesas, Raul Ortiz, Jose Prados, Gloria Perazzoli
Background: Liposomal Doxorubicin (Doxil®) was one of the first nanoformulations approved for the treatment of solid tumors. Although there is already extensive experience in its use for different tumors, there is currently no grouped evidence of its therapeutic benefits in non-small cell lung cancer (NSCLC). A systematic review of the literature was performed on the therapeutic effectiveness and benefits of Liposomal Doxil® in NSCLC. Methods: A total of 1022 articles were identified in publications up to 2020 (MEDLINE, Cochrane, Web of Science Core Collection and Scopus). After applying inclusion criteria, the number was restricted to 114, of which 48 assays, including in vitro (n=20) and in vivo (animals, n=35 and humans, n=6) studies, were selected. Results: The maximum inhibitory concentration (IC50), tumor growth inhibition rate, response and survival rates were the main indices for evaluating the efficacy and effectiveness of Liposomal DOX. These have shown clear benefits both in vitro and in vivo, improving the IC50 of free DOX or untargeted liposomes, depending on their size, administration, or targeting. Conclusion: Doxil® significantly reduced cellular proliferation in vitro and improved survival in vivo in both experimental animals and NSCLC patients, demonstrating optimal safety and pharmacokinetic behavior indices. Although our systematic review supports its benefits for the treatment of NSCLC, additional clinical trials with larger sample sizes are necessary to obtain more precise clinical data on its activity and effects in humans.
背景:多柔比星脂质体(Doxil®)是首批获准用于治疗实体瘤的纳米制剂之一。虽然在不同肿瘤的治疗方面已有丰富的经验,但目前还没有一组证据表明其对非小细胞肺癌(NSCLC)的治疗效果。我们就多西尔脂质体®对 NSCLC 的治疗效果和益处进行了系统性的文献综述。方法:在截至 2020 年的出版物(MEDLINE、Cochrane、Web of Science Core Collection 和 Scopus)中共发现 1022 篇文章。应用纳入标准后,数量限制在 114 篇,其中选择了 48 项检测,包括体外(20 篇)和体内(动物 35 篇,人类 6 篇)研究。研究结果最大抑制浓度(IC50)、肿瘤生长抑制率、反应率和存活率是评价 Liposomal DOX 疗效的主要指标。根据脂质体的大小、给药方式或靶向性,这些指标在体外和体内都显示出明显的优势,提高了游离 DOX 或非靶向脂质体的 IC50。结论在实验动物和 NSCLC 患者体内,Doxil® 可明显减少体外细胞增殖,提高体内存活率,并显示出最佳的安全性和药代动力学行为指数。尽管我们的系统性综述支持多吉美治疗 NSCLC 的益处,但仍有必要进行更多样本量更大的临床试验,以获得有关多吉美在人体中的活性和效果的更精确临床数据。
{"title":"Liposomal Doxorubicin In vitro and In vivo Assays in Non-small Cell Lung Cancer: A Systematic Review","authors":"Pablo Redruello-Guerrero, Paula Cordoba, Antonio Láinez-Ramos-Bossini, Mario Rivera, Cristina Mesas, Raul Ortiz, Jose Prados, Gloria Perazzoli","doi":"10.2174/0115672018272162231116093143","DOIUrl":"https://doi.org/10.2174/0115672018272162231116093143","url":null,"abstract":"Background: Liposomal Doxorubicin (Doxil®) was one of the first nanoformulations approved for the treatment of solid tumors. Although there is already extensive experience in its use for different tumors, there is currently no grouped evidence of its therapeutic benefits in non-small cell lung cancer (NSCLC). A systematic review of the literature was performed on the therapeutic effectiveness and benefits of Liposomal Doxil® in NSCLC. Methods: A total of 1022 articles were identified in publications up to 2020 (MEDLINE, Cochrane, Web of Science Core Collection and Scopus). After applying inclusion criteria, the number was restricted to 114, of which 48 assays, including in vitro (n=20) and in vivo (animals, n=35 and humans, n=6) studies, were selected. Results: The maximum inhibitory concentration (IC50), tumor growth inhibition rate, response and survival rates were the main indices for evaluating the efficacy and effectiveness of Liposomal DOX. These have shown clear benefits both in vitro and in vivo, improving the IC50 of free DOX or untargeted liposomes, depending on their size, administration, or targeting. Conclusion: Doxil® significantly reduced cellular proliferation in vitro and improved survival in vivo in both experimental animals and NSCLC patients, demonstrating optimal safety and pharmacokinetic behavior indices. Although our systematic review supports its benefits for the treatment of NSCLC, additional clinical trials with larger sample sizes are necessary to obtain more precise clinical data on its activity and effects in humans.","PeriodicalId":10842,"journal":{"name":"Current drug delivery","volume":"292 1 1","pages":""},"PeriodicalIF":2.4,"publicationDate":"2023-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138684625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mechanism of Action and Related Natural Regulators of Nrf2 in Nonalcoholic Fatty Liver Disease Nrf2在非酒精性脂肪性肝病中的作用机制及相关天然调节因子
4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2023-10-30 DOI: 10.2174/0115672018260113231023064614
Wenfei Yu, Decheng Meng, Xin Zhang, Yanan Feng, Guoliang Yin, Pengpeng Liang, Suwen Chen, Hongshuai Liu, Fengxia Zhang
Abstract:: With the acceleration of people's pace of life, non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease in the world, which greatly threatens people's health and safety. Therefore, there is still an urgent need for higher-quality research and treatment in this area. Nuclear factor Red-2-related factor 2 (Nrf2), as a key transcription factor in the regulation of oxidative stress, plays an important role in inducing the body's antioxidant response. Although there are no approved drugs targeting Nrf2 to treat NAFLD so far, it is still of great significance to target Nrf2 to alleviate NAFLD. In recent years, studies have reported that many natural products treat NAFLD by acting on Nrf2 or Nrf2 pathways. This article reviews the role of Nrf2 in the pathogenesis of NAFLD and summarizes the currently reported natural products targeting Nrf2 or Nrf2 pathway for the treatment of NAFLD, which provides new ideas for the development of new NAFLD-related drugs.
摘要:随着人们生活节奏的加快,非酒精性脂肪性肝病(NAFLD)已成为世界上最常见的慢性肝病,极大地威胁着人们的健康和安全。因此,在这一领域仍迫切需要更高质量的研究和治疗。核因子Red-2-related factor 2 (Nrf2)作为调控氧化应激的关键转录因子,在诱导机体抗氧化反应中起着重要作用。虽然目前尚无批准的靶向Nrf2治疗NAFLD的药物,但靶向Nrf2缓解NAFLD仍具有重要意义。近年来,有研究报道许多天然产物通过作用于Nrf2或Nrf2通路来治疗NAFLD。本文综述了Nrf2在NAFLD发病机制中的作用,并对目前报道的靶向Nrf2或Nrf2通路治疗NAFLD的天然产物进行了总结,为开发新的NAFLD相关药物提供了新的思路。
{"title":"Mechanism of Action and Related Natural Regulators of Nrf2 in Nonalcoholic Fatty Liver Disease","authors":"Wenfei Yu, Decheng Meng, Xin Zhang, Yanan Feng, Guoliang Yin, Pengpeng Liang, Suwen Chen, Hongshuai Liu, Fengxia Zhang","doi":"10.2174/0115672018260113231023064614","DOIUrl":"https://doi.org/10.2174/0115672018260113231023064614","url":null,"abstract":"Abstract:: With the acceleration of people's pace of life, non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease in the world, which greatly threatens people's health and safety. Therefore, there is still an urgent need for higher-quality research and treatment in this area. Nuclear factor Red-2-related factor 2 (Nrf2), as a key transcription factor in the regulation of oxidative stress, plays an important role in inducing the body's antioxidant response. Although there are no approved drugs targeting Nrf2 to treat NAFLD so far, it is still of great significance to target Nrf2 to alleviate NAFLD. In recent years, studies have reported that many natural products treat NAFLD by acting on Nrf2 or Nrf2 pathways. This article reviews the role of Nrf2 in the pathogenesis of NAFLD and summarizes the currently reported natural products targeting Nrf2 or Nrf2 pathway for the treatment of NAFLD, which provides new ideas for the development of new NAFLD-related drugs.","PeriodicalId":10842,"journal":{"name":"Current drug delivery","volume":"18 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136132878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Customizable Microfluidic Devices: Progress, Constraints, and Future Advances 可定制的微流体装置:进展、限制和未来进展
4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2023-10-26 DOI: 10.2174/0115672018264064231017113813
Alaa A. A. Aljabali, Mohammad A. Obeid, Vijay Mishra, Mohamed El-Tanani, Murtaza M. Tambuwala
Abstract: The field of microfluidics encompasses the study of fluid behavior within micro-channels and the development of miniature systems featuring internal compartments or passageways tailored for fluid control and manipulation. Microfluidic devices capitalize on the unique chemical and physical properties exhibited by fluids at the microscopic scale. In contrast to their larger counterparts, microfluidic systems offer a multitude of advantages. Their implementation facilitates the investigation and utilization of reduced sample, solvent, and reagent volumes, thus yielding decreased operational expenses. Owing to their compact dimensions, these devices allow for the concurrent execution of multiple procedures, leading to expedited experimental timelines. Over the past two decades, microfluidics has undergone remarkable advancements, evolving into a multifaceted discipline. Subfields such as organ-on-a-chip and paper-based microfluidics have matured into distinct fields of study. Nonetheless, while scientific progress within the microfluidics realm has been notable, its translation into autonomous end-user applications remains a frontier to be fully explored. This paper sets forth the central objective of scrutinizing the present research paradigm, prevailing limitations, and potential prospects of customizable microfluidic devices. Our inquiry revolves around the latest strides achieved, prevailing constraints, and conceivable trajectories for adaptable microfluidic technologies. We meticulously delineate existing iterations of microfluidic systems, elucidate their operational principles, deliberate upon encountered limitations, and provide a visionary outlook toward the future trajectory of microfluidic advancements. In summation, this work endeavors to shed light on the current state of microfluidic systems, underscore their operative intricacies, address incumbent challenges, and unveil promising pathways that chart the course toward the next frontier of microfluidic innovation.
摘要:微流体领域包括对微通道内流体行为的研究,以及为流体控制和操纵量身定制的具有内部隔间或通道的微型系统的开发。微流控装置利用流体在微观尺度上所表现出的独特的化学和物理性质。与它们的大型对应物相比,微流体系统提供了许多优点。它们的实施有利于减少样品、溶剂和试剂体积的调查和利用,从而降低了操作费用。由于其紧凑的尺寸,这些设备允许并行执行多个程序,导致加速实验时间线。在过去的二十年中,微流体学取得了显著的进步,发展成为一门多方面的学科。诸如器官芯片和基于纸张的微流体等子领域已经成熟为不同的研究领域。尽管如此,虽然微流体领域的科学进步已经显著,但其转化为自主终端用户应用仍然是一个有待充分探索的前沿。本文阐述了审查当前研究范式的中心目标,普遍的局限性,以及可定制微流体装置的潜在前景。我们的调查围绕着最新的进展,普遍的限制,和可想象的轨迹适应性微流控技术。我们细致地描述了现有的微流控系统的迭代,阐明了它们的工作原理,仔细考虑了遇到的局限性,并对微流控技术的未来发展轨迹提供了一个有远见的展望。总而言之,这项工作努力阐明微流控系统的现状,强调其操作的复杂性,解决当前的挑战,并揭示有希望的途径,为微流控创新的下一个前沿指明方向。
{"title":"Customizable Microfluidic Devices: Progress, Constraints, and Future Advances","authors":"Alaa A. A. Aljabali, Mohammad A. Obeid, Vijay Mishra, Mohamed El-Tanani, Murtaza M. Tambuwala","doi":"10.2174/0115672018264064231017113813","DOIUrl":"https://doi.org/10.2174/0115672018264064231017113813","url":null,"abstract":"Abstract: The field of microfluidics encompasses the study of fluid behavior within micro-channels and the development of miniature systems featuring internal compartments or passageways tailored for fluid control and manipulation. Microfluidic devices capitalize on the unique chemical and physical properties exhibited by fluids at the microscopic scale. In contrast to their larger counterparts, microfluidic systems offer a multitude of advantages. Their implementation facilitates the investigation and utilization of reduced sample, solvent, and reagent volumes, thus yielding decreased operational expenses. Owing to their compact dimensions, these devices allow for the concurrent execution of multiple procedures, leading to expedited experimental timelines. Over the past two decades, microfluidics has undergone remarkable advancements, evolving into a multifaceted discipline. Subfields such as organ-on-a-chip and paper-based microfluidics have matured into distinct fields of study. Nonetheless, while scientific progress within the microfluidics realm has been notable, its translation into autonomous end-user applications remains a frontier to be fully explored. This paper sets forth the central objective of scrutinizing the present research paradigm, prevailing limitations, and potential prospects of customizable microfluidic devices. Our inquiry revolves around the latest strides achieved, prevailing constraints, and conceivable trajectories for adaptable microfluidic technologies. We meticulously delineate existing iterations of microfluidic systems, elucidate their operational principles, deliberate upon encountered limitations, and provide a visionary outlook toward the future trajectory of microfluidic advancements. In summation, this work endeavors to shed light on the current state of microfluidic systems, underscore their operative intricacies, address incumbent challenges, and unveil promising pathways that chart the course toward the next frontier of microfluidic innovation.","PeriodicalId":10842,"journal":{"name":"Current drug delivery","volume":"12 2","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134910209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Amlodipine Ocular Delivery Restores Ferning Patterns and Reduces Intensity of Glycosylated Peak of Carrageenan-Induced Tear Fluid: An InSilico Flexible Docking with IL-Β1 氨氯地平眼部给药恢复蕨类植物模式并降低卡拉胶诱导泪液糖基化峰强度:与IL的硅柔性对接-Β1
4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2023-10-26 DOI: 10.2174/0115672018264980231017115829
Ashirbad Nanda, Rudra Narayan Sahoo, Mahendra Gour, Sandeep Kumar Swain, Debajyoti Das, Amit Kumar Nayak, Subrata Mallick
Background: The tear ferning test can be an easy clinical procedure for the evaluation and characterization of the ocular tear film Objective: The objective of this study was to examine the restoration of tear ferning pattern and reduction of glycosylation peak after amlodipine application in carrageenan-induced conjunctivitis. Methods: At the rabbit’s upper palpebral region, carrageenan was injected for cytokine-mediated conjunctivitis. Ferning pattern and glycosylation of the tear fluid were characterized using various instrumental analyses. The effect of amlodipine was also examined after ocular instillation and flexible docking studies. Results: Optical microscopy showed a disrupted ferning of the tear collected from the inflamed eye. FTIR of the induced tear fluid exhibited peaks within 1000-1200 cm-1 , which might be due to the protein glycosylation, which was absent in the normal tear spectrogram. The glycosylation peak reduced significantly in the tear sample collected from the amlodipine-treated group. Corresponding energy dispersive analysis showed the presence of sulphur, indicating protein leakage from the lacrimal gland in the induced group. The disappearance of sulphur from the treated group indicated its remedial effect. The flexible docking studies revealed a stronger binding mode of amlodipine with Interleukin-1β (IL-1β). The reduction in the intensity of the glycosylated peak and the restoration offering is probably due to suppression of IL-1β. Conclusion: This study may be helpful in obtaining primary information for drug discovery to be effective against IL-1β and proving tear fluid as a novel diagnostic biomarker.
目的:本研究旨在探讨氨氯地平应用于卡拉胶性结膜炎后泪蕨形态的恢复和糖基化峰的降低。方法:在家兔上睑区注射卡拉胶治疗细胞因子介导的结膜炎。泪液的蕨类模式和糖基化用各种仪器分析表征。在眼滴注和柔性对接研究后也检查了氨氯地平的效果。结果:光学显微镜显示从发炎的眼睛收集的泪液的蕨类植物被破坏。诱导泪液的FTIR在1000-1200 cm-1范围内显示出峰值,这可能是由于正常泪液谱图中不存在的蛋白质糖基化所致。氨氯地平组泪液中糖基化峰明显降低。相应的能量色散分析显示有硫的存在,提示诱导组泪腺有蛋白质渗漏。治疗组中硫的消失说明其治疗效果。柔性对接研究显示氨氯地平与白细胞介素-1β (IL-1β)的结合模式更强。糖基化峰强度的降低和恢复提供可能是由于IL-1β的抑制。结论:本研究为开发抗IL-1β药物提供了初步信息,并证明泪液是一种新的诊断性生物标志物。
{"title":"Amlodipine Ocular Delivery Restores Ferning Patterns and Reduces Intensity of Glycosylated Peak of Carrageenan-Induced Tear Fluid: An InSilico Flexible Docking with IL-Β1","authors":"Ashirbad Nanda, Rudra Narayan Sahoo, Mahendra Gour, Sandeep Kumar Swain, Debajyoti Das, Amit Kumar Nayak, Subrata Mallick","doi":"10.2174/0115672018264980231017115829","DOIUrl":"https://doi.org/10.2174/0115672018264980231017115829","url":null,"abstract":"Background: The tear ferning test can be an easy clinical procedure for the evaluation and characterization of the ocular tear film Objective: The objective of this study was to examine the restoration of tear ferning pattern and reduction of glycosylation peak after amlodipine application in carrageenan-induced conjunctivitis. Methods: At the rabbit’s upper palpebral region, carrageenan was injected for cytokine-mediated conjunctivitis. Ferning pattern and glycosylation of the tear fluid were characterized using various instrumental analyses. The effect of amlodipine was also examined after ocular instillation and flexible docking studies. Results: Optical microscopy showed a disrupted ferning of the tear collected from the inflamed eye. FTIR of the induced tear fluid exhibited peaks within 1000-1200 cm-1 , which might be due to the protein glycosylation, which was absent in the normal tear spectrogram. The glycosylation peak reduced significantly in the tear sample collected from the amlodipine-treated group. Corresponding energy dispersive analysis showed the presence of sulphur, indicating protein leakage from the lacrimal gland in the induced group. The disappearance of sulphur from the treated group indicated its remedial effect. The flexible docking studies revealed a stronger binding mode of amlodipine with Interleukin-1β (IL-1β). The reduction in the intensity of the glycosylated peak and the restoration offering is probably due to suppression of IL-1β. Conclusion: This study may be helpful in obtaining primary information for drug discovery to be effective against IL-1β and proving tear fluid as a novel diagnostic biomarker.","PeriodicalId":10842,"journal":{"name":"Current drug delivery","volume":"3 2","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134910348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Extraction, characterization and controlled release application of pectin-like/chitosan hydrogels system loaded Ciprofloxacin. 类果胶/壳聚糖水凝胶环丙沙星的提取、表征及控释应用。
IF 2.4 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2023-09-01 DOI: 10.2174/1567201821666230901153513
Amer Rashid Hameed, Zeineb Mzoughi, Mariem Itaimi Dammak, Fawzi Habeeb Jabrail, Didier Le Cerf, Hatem Majdoub

Introduction: In recent decades, drug delivery applications have extensively utilized hydrogel systems based on natural polymers. Among the numerous biopolymer-based hydrogel drug delivery systems reported, a novel pectin-like substance was extracted from fig leaves and copolymerized with chitosan.

Method: The hydrogel was reformed into microspheres using glutaraldehyde (chemical cross-linker) and sodium hexametaphosphate (physical cross-linker). The extracted polysaccharide and the prepared hydrogels were characterized by FTIR, GC/MS, SEC/MALS/DRI as well as XRD, SEM, BET, and thermal analysis. SEM images revealed the formation of porous microspheres with an average size of 50 μm in diameter. Degrees of swelling in pH7 at 35°C have shown the hydrogels reached two to three times their weights. This has been reflected in their ability to load drugs or any other chemicals. The loading formula shows that hydrogels have maximum loading efficiency more than one-third of the weight of hydrogel. The antimicrobial ciprofloxacin was used as a model for loading on prepared hydrogels. The loaded hydrogels were tested for their biological activities against staphylococcus aureus (S. aureus) bacteria. The antimicrobial growth inhibition zone of the cultured (S. aureus) by ciprofloxacin-loaded hydrogel was followed, which shows controlled growth in inhibition zone sizes and for long time intervals. Results showed that the pectin-chitosan hydrogels exhibited significant antibacterial activity against gram - positive bacteria (S. aureus), with an inhibition zone of 45 mm for (CH-co-FLP)/GLU hydrogel.

Result: In vitro, the ciprofloxacin-loaded hydrogels were studied and the cumulative release of ciprofloxacin under suitable conditions was found in a controlled manner and kept release for a long time interval. Data exhibited that the cumulative release profile of ciprofloxacin from the hydrogel demonstrated sustained release over 48 hours, with a value of 6.9% released within the first 24 hours and 7.0 and 6.9% % released at the end of the study for the (CH-co-FLP)/GLU and (CH-co-FLP)/SMP hydrogels, respectively.

Conclusion: The novel pectin-chitosan hydrogels hold the potential to enhance the quality of life for numerous patients by minimizing the need for frequent intake of chronic medications.

近几十年来,药物递送应用广泛使用基于天然聚合物的水凝胶系统。在众多以生物聚合物为基础的水凝胶给药系统中,从无花果叶中提取了一种新型的类似果胶的物质,并与壳聚糖共聚。方法:用戊二醛(化学交联剂)和六偏磷酸钠(物理交联剂)将水凝胶改造成微球。通过FTIR、GC/MS、SEC/MALS/DRI、XRD、SEM、BET和热分析对提取的多糖和制备的水凝胶进行表征。SEM图像显示形成了平均直径为50 μm的多孔微球。在35°C下pH7的膨胀程度表明水凝胶达到其重量的两到三倍。这反映在它们装载药物或任何其他化学品的能力上。加载公式表明,水凝胶的最大加载效率大于水凝胶重量的三分之一。以抗菌药物环丙沙星为模型,在制备的水凝胶上进行负载。研究了负载水凝胶对金黄色葡萄球菌(S. aureus)细菌的生物活性。经环丙沙星负载水凝胶培养的金黄色葡萄球菌抗菌生长抑制带,抑制带大小和生长时间间隔均有控制。结果表明,果胶-壳聚糖水凝胶对革兰氏阳性菌(金黄色葡萄球菌)具有明显的抑菌活性,对(CH-co-FLP)/GLU水凝胶的抑菌带为45 mm。结果:体外对环丙沙星载水凝胶进行了研究,发现环丙沙星在适宜条件下的累积释放量可控,且缓释时间长。数据显示,环丙沙星在水凝胶中的累积释放量在48小时内持续释放,其中(CH-co-FLP)/GLU和(CH-co-FLP)/SMP水凝胶在研究结束时的释放量分别为7.0%和6.9%。结论:新型果胶-壳聚糖水凝胶通过减少频繁服用慢性药物的需要,有可能提高许多患者的生活质量。
{"title":"Extraction, characterization and controlled release application of pectin-like/chitosan hydrogels system loaded Ciprofloxacin.","authors":"Amer Rashid Hameed,&nbsp;Zeineb Mzoughi,&nbsp;Mariem Itaimi Dammak,&nbsp;Fawzi Habeeb Jabrail,&nbsp;Didier Le Cerf,&nbsp;Hatem Majdoub","doi":"10.2174/1567201821666230901153513","DOIUrl":"https://doi.org/10.2174/1567201821666230901153513","url":null,"abstract":"<p><strong>Introduction: </strong>In recent decades, drug delivery applications have extensively utilized hydrogel systems based on natural polymers. Among the numerous biopolymer-based hydrogel drug delivery systems reported, a novel pectin-like substance was extracted from fig leaves and copolymerized with chitosan.</p><p><strong>Method: </strong>The hydrogel was reformed into microspheres using glutaraldehyde (chemical cross-linker) and sodium hexametaphosphate (physical cross-linker). The extracted polysaccharide and the prepared hydrogels were characterized by FTIR, GC/MS, SEC/MALS/DRI as well as XRD, SEM, BET, and thermal analysis. SEM images revealed the formation of porous microspheres with an average size of 50 μm in diameter. Degrees of swelling in pH7 at 35°C have shown the hydrogels reached two to three times their weights. This has been reflected in their ability to load drugs or any other chemicals. The loading formula shows that hydrogels have maximum loading efficiency more than one-third of the weight of hydrogel. The antimicrobial ciprofloxacin was used as a model for loading on prepared hydrogels. The loaded hydrogels were tested for their biological activities against staphylococcus aureus (S. aureus) bacteria. The antimicrobial growth inhibition zone of the cultured (S. aureus) by ciprofloxacin-loaded hydrogel was followed, which shows controlled growth in inhibition zone sizes and for long time intervals. Results showed that the pectin-chitosan hydrogels exhibited significant antibacterial activity against gram - positive bacteria (S. aureus), with an inhibition zone of 45 mm for (CH-co-FLP)/GLU hydrogel.</p><p><strong>Result: </strong>In vitro, the ciprofloxacin-loaded hydrogels were studied and the cumulative release of ciprofloxacin under suitable conditions was found in a controlled manner and kept release for a long time interval. Data exhibited that the cumulative release profile of ciprofloxacin from the hydrogel demonstrated sustained release over 48 hours, with a value of 6.9% released within the first 24 hours and 7.0 and 6.9% % released at the end of the study for the (CH-co-FLP)/GLU and (CH-co-FLP)/SMP hydrogels, respectively.</p><p><strong>Conclusion: </strong>The novel pectin-chitosan hydrogels hold the potential to enhance the quality of life for numerous patients by minimizing the need for frequent intake of chronic medications.</p>","PeriodicalId":10842,"journal":{"name":"Current drug delivery","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10553355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Integrated animal experiments and network pharmacology for investigating therapeutic effect of celastrol-loaded liposomes on NAFLD. 结合动物实验和网络药理学研究了罗汉素脂质体对NAFLD的治疗作用。
IF 2.4 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2023-08-10 DOI: 10.2174/1567201821666230810094643
Jingbin Shi, Ninghui Ma, Ningchao Luo, Jingyi Huang, Shujun Xu, Yang Xiong

Background: The prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) is closely related to the increase of the incidence rate of obesity.

Aims: To find out the targets of celastrol on NAFLD with the treatment of celastrol-loaded liposomes (Cel-Lips).

Methods: Gene Expression Omnibus (GEO) data were used to compare the expression of differential genes in NAFLD patients with normal individuals. Celastrol was loaded into liposomes to improve its solubility, as well as, achieving a passive targeting effect on the liver to improve the availability, which also could delay the release rate of celastrol to prolong the action time and thus reduce the frequency of administration. Due to rarely reported molecular mechanisms of celastrol, with the help of network pharmacological analysis, the targets of celastrol acting on NAFLD were predictively analyzed.

Results: An association between NAFLD and lipid metabolism was detected in GEO data. Cel-Lips significantly alleviated NAFLD in vivo. Through network pharmacology, it was found that most of the action pathways of celastrol were related to lipid metabolism.

Conclusion: Celastrol has the potential to treat NAFLD, and its possible targets have been identified through network pharmacological screening, which provides a certain basis for the follow-up researches.

背景:非酒精性脂肪性肝病(NAFLD)的患病率与肥胖发病率的增加密切相关。目的:探讨celastrol载脂质体(celastrol- lips)对NAFLD的治疗作用。方法:采用GEO (Gene Expression Omnibus)数据比较NAFLD患者与正常人差异基因的表达。将雷公藤红素加载到脂质体中,提高其溶解度,同时对肝脏产生被动靶向作用,提高利用度,同时延缓雷公藤红素的释放速度,延长作用时间,减少给药频率。由于celastrol的分子机制报道较少,借助网络药理学分析,对celastrol作用于NAFLD的靶点进行了预测分析。结果:在GEO数据中检测到NAFLD与脂质代谢之间的关联。cell - lips在体内显著缓解NAFLD。通过网络药理学研究发现,雷公藤红素的大部分作用途径与脂质代谢有关。结论:Celastrol具有治疗NAFLD的潜力,通过网络药理筛选确定了其可能的靶点,为后续研究提供了一定的依据。
{"title":"Integrated animal experiments and network pharmacology for investigating therapeutic effect of celastrol-loaded liposomes on NAFLD.","authors":"Jingbin Shi,&nbsp;Ninghui Ma,&nbsp;Ningchao Luo,&nbsp;Jingyi Huang,&nbsp;Shujun Xu,&nbsp;Yang Xiong","doi":"10.2174/1567201821666230810094643","DOIUrl":"https://doi.org/10.2174/1567201821666230810094643","url":null,"abstract":"<p><strong>Background: </strong>The prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) is closely related to the increase of the incidence rate of obesity.</p><p><strong>Aims: </strong>To find out the targets of celastrol on NAFLD with the treatment of celastrol-loaded liposomes (Cel-Lips).</p><p><strong>Methods: </strong>Gene Expression Omnibus (GEO) data were used to compare the expression of differential genes in NAFLD patients with normal individuals. Celastrol was loaded into liposomes to improve its solubility, as well as, achieving a passive targeting effect on the liver to improve the availability, which also could delay the release rate of celastrol to prolong the action time and thus reduce the frequency of administration. Due to rarely reported molecular mechanisms of celastrol, with the help of network pharmacological analysis, the targets of celastrol acting on NAFLD were predictively analyzed.</p><p><strong>Results: </strong>An association between NAFLD and lipid metabolism was detected in GEO data. Cel-Lips significantly alleviated NAFLD in vivo. Through network pharmacology, it was found that most of the action pathways of celastrol were related to lipid metabolism.</p><p><strong>Conclusion: </strong>Celastrol has the potential to treat NAFLD, and its possible targets have been identified through network pharmacological screening, which provides a certain basis for the follow-up researches.</p>","PeriodicalId":10842,"journal":{"name":"Current drug delivery","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2023-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9972363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Current drug delivery
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1